Abraxane(R) versus Taxol(R) for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective

Conclusion
To our knowledge, this is first such study in breast cancer patients to be undertaken in China. Abraxane® was associated with fewer acute adverse drug reactions and significant reductions in health care resources, physician/nurse time and overall drug delivery costs compared to Taxol®.

Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Dranitsaris, G., Yu, B., Wang, L., Sun, W., Zhou, Y., King, J., Kaura, S., Zhang, A., Yuan, P. Tags: Original Articles Source Type: research